Wolfe Research analyst Andy Chen reiterated an Outperform rating and $88.00 price target on Vera Therapeutics (NASDAQ: VERA)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Goldman Sachs on Vera Therapeutics (VERA): 'We are encouraged by today's update'June 2, 2026 11:15 AM Raymond James: ''If Vera is successful with this new plan, it could effectively shorten the theoretical lead Otsuka'June 2, 2026 10:12 AM TD Cowen on Vera Therapeutics (VERA): 'Launch prep remains on track; we have confidence in a clean approval'June 2, 2026 7:16 AM Form 8-K Vera Therapeutics, Inc. For: Jun 02June 2, 2026 7:05 AM Vera Therapeutics moves up atacicept analysis timeline with FDA agreementJune 2, 2026 7:00 AM Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyJune 2, 2026 7:00 AM